Akebia Therapeutics, Inc. (AKBA)

Akebia Therapeutics Revenue

Akebia Therapeutics had revenue of $187.23M in the twelve months ending March 31, 2024, down -30.88% year-over-year. Revenue in the quarter ending March 31, 2024 was $32.61M, a -18.49% decrease year-over-year. In the year 2023, Akebia Therapeutics had annual revenue of $194.62M, a decrease of -33.46%.

• Revenue (ttm): $187.23M
• Revenue Growth: -30.88%
• P/S Ratio: 1.32
• Revenue / Employee: $1,121,108
• Employees: 167
• Market Cap: 247.32M USD

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	194.62M	-97.86M	-33.46%
Dec 31, 2022	292.48M	80.83M	38.19%
Dec 31, 2021	211.65M	-82.99M	-28.17%
Dec 31, 2020	294.64M	-40.36M	-12.05%
Dec 31, 2019	335.00M	127.26M	61.26%
Dec 31, 2018	207.74M	26.52M	14.63%
Dec 31, 2017	181.23M	179.69M	11,706.32%
Dec 31, 2016	1.54M	-	-
Dec 31, 2015	0	-	-
Dec 31, 2014	0	-	-
Dec 28, 2013	0	-	-
Dec 31, 2012	0	-	-

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.